India, Oct. 16 -- The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.
With the month yielding a mix of new therapies and expanded treatment options, let's take a closer look at the drugs approved, the conditions they target, and the key pricing details behind them.
1. Zanvastro (Zilganersen)
Developed by: Ionis Pharmaceuticals Inc. (IONS)
Approved on: September 3, 2026
Indication: Alexander disease
Alexander disease (AxD) is a rare, progressive, and ultimately fatal neurological disorder that affects one in every 1 to 3 million individuals. The disorder attacks patients' astrocytes, which ...